Although TMB has a potentially predictive value for anti-PD-1 therapy in MSI-H mCRC patients, the identification of peripheral blood biomarkers is crucial because the access of biomarkers from the blood is easier than that from tumor tissues. The gene discussed is PDCD1; the disease is neoplasm.